Cerus Corporation

CERS Healthcare Medical Devices

In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.

2.20 0.06 −2.65%
Market cap
$455.5M
P/E
0.0×
Fwd P/E
−81.3×
Dividend yield
—
F-score
5/9
Altman Z
−4.00
Beneish M
−2.87
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.35 1.68 1.44 2.36
P/FCF ratio
1,815.53 354.35 0.00 0.00
P/Operating CF
158.28 63.33 (115.89) (220.09)
P/B ratio
4.90 6.04 5.17 8.28
EV/Sales
1.38 1.68 1.46 2.40
EV/EBITDA
0.00 0.00 0.00 9,004.57
EV/FCF
1,853.58 355.26 (293.71) (324.93)
Current Ratio
1.89 1.73 1.63 1.83
Net Debt/EBITDA
3.95 (4.07) 47.38 (6.19)
Debt/Equity
1.36 1.29 1.24 0.92
Earnings Yield
(5.25%) (3.89%) (2.75%) (1.20%)
Free Cash Flow Yield
0.06% 0.28% (0.34%) (0.31%)
Free Cash Flow per Share
0.00 0.03 (0.02) (0.02)
Book value per Share
0.32 0.34 0.35 0.35
Free Cash Flow
0.09 4.89 (3.28) (3.53)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates